跳至主要内容
临床试验/jRCT2032200147
jRCT2032200147已完成不适用

Clinical Investigation of AcrySof IQ PanOptix Toric Intraocular Lens Model TFNT20

Alcon Japan Ltd.0 个研究点目标入组 32 人开始时间: 2020年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized Controlled Trial
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
20age old over 至 No limit(—)
性别
All

入选标准

  • Eligible to be implanted with AcrySof IQ PanOptix Toric Intraocular Lens Model TFNT20 in at least one eye as determined by a new Alcon Toric calculator.
  • Planned postoperative emmetropia (spherical equivalent +-0.50 D).
  • Other protocol-specified inclusion criteria may apply.

排除标准

  • Irregular corneal astigmatism.
  • History of anterior segment (corneal, anterior chamber, sulcus) or posterior segment (uveal, vitreo-retinal) pathology.
  • Glaucoma; ocular hypertension; diabetic retinopathy; any optic nerve pathology.
  • History of previous intraocular or corneal (refractive or trauma related) surgery.
  • Any other planned ocular surgical procedures including but not limited to limbal relaxing incision (LRI)/Astigmatic Keratotomy and LASIK.
  • Other protocol-defined exclusion criteria may apply.

结局指标

主要结局

-

Percentage of eyes with <= 0.25 diopter (D) refractive cylinder at Visit 3/3A (Day 30-60).

次要结局

  • Percentage of eyes with <= 0.5 D refractive cylinder(Visit 3/3A (Day 30-60))
  • Average manifest refractive cylinder(Visit 3/3A (Day 30-60))

研究者

相似试验